Reference - Detail
| RRC ID | 39792 |
|---|---|
| Author | Satoh J, Kuroda Y. |
| Title | Beta-catenin expression in human neural cell lines following exposure to cytokines and growth factors. |
| Journal | Neuropathology |
| Abstract |
Beta-catenin acts as a key mediator of the Wnt/Wingless signaling pathway involved in cell proliferation, differentiation and survival. Recent studies have shown that an unstable interaction between beta-catenin and the mutant presenilin-1 induces neuronal apoptosis, and that beta-catenin levels are decreased in the brains of patients with Alzheimer's disease (AD). Since activated microglia and astrocytes play a role in the process of neuronal degeneration in AD, the cytokine/growth factor-regulated expression of beta-catenin in human neural cell lines, including NTera2 teratocarcinoma-derived differentiated neurons (NTera2-N), IMR-32 neuroblastoma, SKN-SH neuroblastoma and U-373MG astrocytoma, was studied quantitatively following exposure to epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), brain-derived neurotrophic factor (BDNF), tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1beta, IL-6, interferon (IFN)-gamma, transforming growth factor (TGF)-beta1, dibutyryl cyclic adenosine 3',5'-cyclic monophosphate (cAMP) (dbcAMP) or phorbol 12-myristate 13-acetate (PMA). Beta-catenin mRNA expressed constitutively in all of these cell lines was unaffected by treatment with any factors examined. In contrast, beta-catenin protein levels were reduced markedly in NTera2-N cells by exposure to dbcAMP, EGF or bFGF, and in U-373MG cells by treatment with dbcAMP or PMA, but were unaffected in any cell lines by BDNF, TNF-alpha, IL-1beta, IL-6, IFN-gamma or TGF-beta1. These results indicate that beta-catenin is expressed constitutively in human neural cells and downregulated at a protein level by a set of growth factors in a cell type-specific manner. |
| Volume | 20(2) |
| Pages | 113-23 |
| Published | 2000-6-1 |
| DOI | 10.1046/j.1440-1789.2000.00293.x |
| PMID | 10935448 |
| MeSH | Astrocytoma Brain Neoplasms Bucladesine / pharmacology Cadherins / genetics Cell Differentiation Cytokines / pharmacology* Cytoskeletal Proteins / genetics* Gene Expression Regulation, Neoplastic / drug effects* Glioma Growth Substances / pharmacology* HL-60 Cells HeLa Cells Humans Neuroblastoma Neurons / cytology Neurons / drug effects Neurons / physiology* Retinal Neoplasms Retinoblastoma Tetradecanoylphorbol Acetate / pharmacology Trans-Activators* Transcription, Genetic / drug effects* Tumor Cells, Cultured beta Catenin |
| IF | 1.758 |
| Times Cited | 29 |
| WOS Category | PATHOLOGY CLINICAL NEUROLOGY NEUROSCIENCES |
| Altmetric score |
オルトメトリクス指標項目
|
| The most frequently cited source | Patent(IFI CLAIMS) |
| Total number of mentions | 3 |
| Altmetric score changes over past 6months | 0.0 |
| Resource | |
| Human and Animal Cells | A549(RCB0098) MOLT-4(RCB0206) HeLa(RCB0007) KG-1-C(RCB0270) |